Article thumbnail

Net Reclassification Improvement (NRI) and Clinical NRI for Various Endpoints for Baseline Troponin Assessed by Contemporary-Sensitivity, High-Sensitivity and Super-Sensitivity Assays in Addition to the Standard Framingham Risk Score.

By Johannes Tobias Neumann (530363), Aki S. Havulinna (120329), Tanja Zeller (112753), Sebastian Appelbaum (530364), Tarja Kunnas (530365), Seppo Nikkari (530366), Pekka Jousilahti (131538), Stefan Blankenberg (112702), Karsten Sydow (301423) and Veikko Salomaa (62543)


<p>NRI = net reclassification improvement, clinical NRI = NRI for individuals with an intermediate 10-year risk (5–20%) according to the Framingham Risk Score, MACE = major adverse cardiac events, CVD = cardiovascular disease, MI = myocardial infarction, HF = heart failure, cs-cTnI = troponin I measured by contemporary-sensitivity assay, hs-cTnI = troponin I measured by high-sensitivity assay, ss-cTnI = troponin I measured by super-sensitivity assay, ns = not significant.</p

Topics: Medicine, cardiovascular, Acute cardiovascular problems, Heart failure, Myocardial infarction, stroke, Clinical research design, Cross-sectional studies, Diagnostic medicine, pathology, General pathology, biomarkers, epidemiology, Biomarker epidemiology, Cardiovascular disease epidemiology, reclassification, nri, endpoints, baseline, troponin, high-sensitivity, super-sensitivity, assays, framingham
Year: 2014
DOI identifier: 10.1371/journal.pone.0090063.t004
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.